By: IPP Bureau
Last updated : January 30, 2026 7:25 pm
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
Vimta Labs Limited, a leading Indian Contract Research and Testing Organisation, has posted steady growth for Q3 and the first nine months of FY26.
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year, while EBITDA stood at Rs. 344 million with a 34.3% margin. Profit after tax (PAT) was Rs. 176 million, maintaining a 17.5% margin, and basic EPS came in at Rs. 3.96.
For the nine months ended December 31, 2025, Vimta Labs recorded total income of Rs. 3,043 million, up 20.7% YoY, with EBITDA of Rs. 1,068 million (16.7% growth) and PAT of Rs. 564 million (16.4% growth).
Commenting on the results, Harita Vasireddi, Managing Director, said: "I am pleased to share that this quarter has been a positive one for Vimta Labs, with total income of Rs. 1,005 mn, reflecting a YoY growth of 10.2%. This performance underscores our continued focus on excellence in scientific research, operational discipline, and customer trust.
"Strong demand across our service offerings, coupled with improved operational efficiencies, has resulted in healthy growth and resilient EBITDA margins of 34.3% (after considering Exceptional item – New Labour Codes impact). Our teams have demonstrated exceptional commitment to quality, enabling us to further strengthen Vimta’s position as a preferred partner for both regulated and emerging markets. Looking ahead, we remain confident in our strategic direction and will continue to invest in capabilities that enhance long-term value for our clients, stakeholders, and the broader people wellness ecosystem.”
The company also noted that prior period figures have been regrouped for comparability following the sale of its Diagnostic and Pathological services business to Thyrocare Technologies in October 2024.